Physician profile
Mallory E Fox
NPI 1760866040
$1,106.26
in general payments reported to CMS, 2019-2025
12 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $228 · 2023: $145 · 2024: $264 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $381.08 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $254.33 | 2024-2025 | Repatha, Otezla, Otezla |
| Corcept Therapeutics | $223.83 | 2022-2023 | Korlym |
| Otsuka America Pharmaceutical, INC. | $62.47 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.72 | 2025 | Caplyta |
| Recordati_rare_diseases_inc. | $29.11 | 2023 | Isturisa |
| Abbott Laboratories | $23.63 | 2022 | |
| Phadia US INC. | $20.89 | 2024 | Immunocap |
| Pfizer INC. | $16.82 | 2025 | |
| Alkermes, INC. | $15.79 | 2023 | Vivitrol |
| Idorsia Pharmaceuticals US INC | $15.75 | 2023 | Quviviq |
| Astellas Pharma US INC | $12.84 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.